ATRA - Atara Biotherapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
ATRA price evolution
ATRA
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $31.46 | $35.23 | $25.99 | |
| Short term investments | $3.98 | $11.15 | $25.88 | |
| Net receivables | $1.33 | $2.42 | $35.83 | $34.11 |
| Inventory | $13.98 | $18.75 | $16.08 | $9.71 |
| Total current assets | $91.86 | $62.41 | $106.43 | $101.87 |
| Long term investments | ||||
| Property, plant & equipment | $47.49 | $51.27 | $54.97 | $58.79 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $54.87 | $58.84 | $63.63 | |
| Total investments | $3.98 | $11.15 | $25.88 | |
| Total assets | $142.71 | $117.28 | $165.27 | $165.5 |
| Current liabilities | ||||
| Accounts payable | $2.15 | $5.25 | $2.85 | $3.68 |
| Deferred revenue | $108.15 | $123.87 | $115.39 | |
| Short long term debt | ||||
| Total current liabilities | $155.98 | $148.27 | $180.69 | $142.23 |
| Long term debt | $37.58 | $36.45 | $77.77 | $80.32 |
| Total noncurrent liabilities | $79.89 | $82.89 | $122.51 | |
| Total debt | $75.15 | $77.77 | $80.32 | |
| Total liabilities | $233.25 | $228.15 | $263.58 | $264.74 |
| Shareholders' equity | ||||
| Retained earnings | -$2041.86 | -$2019.95 | -$2000.9 | -$1969.15 |
| Other shareholder equity | $0.02 | -$0.01 | -$0.06 | -$0.2 |
| Total shareholder equity | -$110.87 | -$98.31 | -$99.23 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $25.99 | $93.09 | $106.28 | $200.6 |
| Short term investments | $25.88 | $149.88 | $264.98 | $300.25 |
| Net receivables | $34.11 | $40.22 | $0.99 | $1.25 |
| Inventory | $9.71 | $1.59 | ||
| Total current assets | $101.87 | $295.08 | $384.62 | $523.27 |
| Long term investments | $1.2 | $1.2 | ||
| Property, plant & equipment | $58.79 | $74.32 | $79.94 | $62.82 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $63.63 | $81.34 | $83.51 | $64.85 |
| Total investments | $25.88 | $149.88 | $266.18 | $301.45 |
| Total assets | $165.5 | $376.42 | $468.13 | $588.12 |
| Current liabilities | ||||
| Accounts payable | $3.68 | $6.87 | $17.37 | $7.12 |
| Deferred revenue | $115.39 | $85 | $96.47 | $61.25 |
| Short long term debt | ||||
| Total current liabilities | $142.23 | $78.92 | $105.79 | $82.9 |
| Long term debt | $80.32 | $3.64 | $25.52 | $13.04 |
| Total noncurrent liabilities | $122.51 | $170.86 | $82.73 | $42.88 |
| Total debt | $80.32 | $88.3 | $25.52 | $13.04 |
| Total liabilities | $264.74 | $249.78 | $188.51 | $125.78 |
| Shareholders' equity | ||||
| Retained earnings | -$1969.15 | -$1693.02 | -$1464.72 | -$1124.58 |
| Other shareholder equity | -$0.2 | -$2.07 | -$0.37 | $0.3 |
| Total shareholder equity | -$99.23 | $126.64 | $279.61 | $462.34 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $40.19 | $28.64 | $27.36 | $4.25 |
| Cost of revenue | $4.63 | $1.99 | $3.16 | |
| Gross Profit | $32.59 | $24.01 | $25.37 | $1.09 |
| Operating activities | ||||
| Research & development | $33.33 | $45.51 | $49.6 | |
| Selling, general & administrative | $8.91 | $11.11 | $11.45 | |
| Total operating expenses | $54.34 | $42.24 | $56.62 | $61.05 |
| Operating income | -$18.23 | -$31.25 | -$59.96 | |
| Income from continuing operations | ||||
| EBIT | -$17.79 | -$30.57 | -$59.26 | |
| Income tax expense | -$0.02 | $0.02 | $0.01 | |
| Interest expense | -$0.72 | $1.26 | $1.15 | $1.18 |
| Net income | ||||
| Net income | -$21.91 | -$19.05 | -$31.75 | -$60.45 |
| Income (for common shares) | -$19.05 | -$31.75 | -$60.45 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $8.57 | $63.57 | $20.34 | |
| Cost of revenue | $8.89 | |||
| Gross Profit | -$0.31 | $63.57 | $20.34 | |
| Operating activities | ||||
| Research & development | $224.78 | $272.53 | $282 | $244.65 |
| Selling, general & administrative | $50.91 | $71.55 | $78.8 | $64.4 |
| Total operating expenses | $275.69 | $344.09 | $360.8 | $309.05 |
| Operating income | -$276.01 | -$280.51 | -$340.46 | -$309.05 |
| Income from continuing operations | ||||
| EBIT | -$270.83 | -$230.28 | -$340.1 | -$306.61 |
| Income tax expense | $0.01 | $0.01 | $0.05 | $0.01 |
| Interest expense | $5.29 | -$1.99 | ||
| Net income | ||||
| Net income | -$276.13 | -$228.3 | -$340.14 | -$306.62 |
| Income (for common shares) | -$276.13 | -$228.3 | -$340.14 | -$306.62 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$19.05 | -$31.75 | -$60.45 | |
| Operating activities | ||||
| Depreciation | $4.36 | $4.34 | $4.15 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $6.34 | $8.4 | $9.93 | |
| Total cash flows from operations | -$10.64 | -$29.61 | -$50.41 | |
| Investing activities | ||||
| Capital expenditures | -$0.03 | -$0.13 | -$0.04 | |
| Investments | $7.22 | $14.84 | $9.99 | |
| Total cash flows from investing | $5.25 | $7.2 | $14.72 | $9.94 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.2 | $24.37 | $1.55 | |
| Net borrowings | -$0.23 | -$0.23 | -$0.21 | |
| Total cash flows from financing | $59.61 | -$0.32 | $24.14 | $1.51 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $20.61 | -$3.77 | $9.25 | -$38.95 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$276.13 | -$228.3 | -$340.14 | -$306.62 |
| Operating activities | ||||
| Depreciation | $16.62 | $14.57 | $11.29 | $9.79 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $45.39 | $53.84 | $53.87 | $51.35 |
| Total cash flows from operations | -$192.98 | -$270.43 | -$220.52 | -$180.76 |
| Investing activities | ||||
| Capital expenditures | -$1.2 | $90.57 | -$10.58 | -$4.51 |
| Investments | $125.06 | $112.38 | $32.84 | -$116.22 |
| Total cash flows from investing | $123.87 | $202.96 | $22.26 | -$120.73 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.14 | $21.89 | $98.7 | $422.97 |
| Net borrowings | -$0.95 | $30.09 | -$0.25 | -$0.39 |
| Total cash flows from financing | $2.01 | $53.08 | $103.94 | $427.57 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$67.1 | -$14.39 | -$94.32 | $126.09 |
News
Fundamentals
| Market cap | $65.44M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 5.74M |
| Revenue | $100.44M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$133.16M |
| Revenue Q/Q | 1.78K% |
| Revenue Y/Y | 2.11K% |
| P/E ratio | -0.49 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.65 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$23.20 |
|---|---|
| ROA | -90.16% |
| ROE | N/A |
| Debt/Equity | -2.67 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.59 |
| Quick ratio | 0.50 |